The state of Louisiana currently has 6 active clinical trials seeking participants for Dementia research studies. These trials are conducted in various cities, including New Orleans, Baton Rouge, Shreveport and Metairie.
Reducing African American's Alzheimer's Risk Through Exercise-Mild Cognitive Impairment (RAATE-MCI)
Recruiting
The RAATE-MCI proposal is designed to determine the effects of physical activity on risk factors for Alzheimer's Disease in older African American adults. The study will compare a physical activity program to an active control group. RAATE-MCI is a 52-week randomized controlled trial. 144 African American adults aged 60 and older will be recruited.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
03/12/2025
Locations: Pennington Biomedical Research, Baton Rouge, Louisiana
Conditions: Dementia of Alzheimer Type
Life's End Benefits of CannaBidiol and TetrahYdrocannabinol
Recruiting
This is a multicenter randomized double-blind placebo-controlled Phase 2 study of an oral combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) compared to placebo over 12 weeks. This study is designed to test the hypothesis that treatment with an oral combination of THC/CBD will reduce agitation hospice care-eligible patients with agitation and dementia as measured by the Cohen Mansfield Agitation Inventory (CMAI) when compared to placebo at 2 weeks. This study will enroll approximat... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/28/2025
Locations: Pennington Biomedical Research Center, Baton Rouge, Louisiana
Conditions: Agitation, Dementia
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
Recruiting
Researchers want to learn if giving MK-1167 (the study medicine) along with acetylcholinesterase inhibitor (AChEI) therapy can improve symptoms of Alzheimer's disease dementia (AD dementia), such as memory and mental activity. AD dementia is the most common type of dementia. AChEI therapy is the standard treatment for AD dementia. The goals of this study are to learn: * If at least one dose level (amount) of MK-1167 works to improve a person's memory and thinking compared to a placebo * About... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
02/26/2025
Locations: Tandem Clinical Research ( Site 0101), Marrero, Louisiana
Conditions: Alzheimer Disease, Dementia
Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey
Recruiting
There is a major unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and dementia. MCI impacts 12-18% of people in the United States over age 60 years (Alzheimer's Association. Mild Cognitive Impairment (MCI) available at https://www.alz.org/alzheimers-dementia/what-is-dementia/related_conditions/mild-cognitive-impairment. Accessed August 16, 2022). MCI does not substantially interfere with daily activities, although complex... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
01/13/2025
Locations: Tulane Doctors Neurosurgery Clinic, New Orleans, Louisiana
Conditions: Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline, Cognitive Impairment, Memory Impairment
Reducing African Americans' Alzheimer's Disease Risk Through Exercise (RAATE)"
Recruiting
The RAATE proposal is designed to determine the effects of physical activity on risk factors for Alzheimer's Disease in older African American adults. The study will compare a physical activity program to an active control group. There are three main objectives of the protocol: 1) to determine if a physical activity intervention tailored to older African American adults is effective in modifying cognitive function associated with Alzheimer's Disease, 2) to determine if a physical activity interv... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
11/20/2024
Locations: Pennington Biomedical Research Center, Baton Rouge, Louisiana
Conditions: Dementia, Alzheimer Type
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
Recruiting
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.
Gender:
All
Ages:
75 years and above
Trial Updated:
06/14/2024
Locations: University Medical Center, New Orleans, Louisiana +1 locations
Conditions: Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases